Anaptysbio (ANAB) Cash from Investing Activities (2016 - 2026)

Anaptysbio has reported Cash from Investing Activities for 11 years, with the latest figure at $35.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 135.62% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $248.2 million (up 496.14% YoY), and the FY2025 full-year result was $228.0 million, up 139.03% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $35.0 million, down from $73.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $103.3 million in Q3 2025, with the low at -$312.9 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged $6.4 million across 5 years, with a median of $30.6 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 651.59% — and 2025, when it surged 1590.7%.
• Anaptysbio's Cash from Investing Activities stood at $21.5 million in 2022, then surged by 128.77% to $49.2 million in 2023, then tumbled by 159.77% to -$29.4 million in 2024, then jumped by 350.03% to $73.5 million in 2025, then slumped by 52.4% to $35.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $35.0 million (Q1 2026), $73.5 million (Q4 2025), and $103.3 million (Q3 2025), per Business Quant data.